WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Kürzel: WX8 Forum: Aktien User: Summer.76

WuXi AppTec Yingxi and its subsidiary WuXi Biologics reach new highs https://www.881903.com/news/finance/2375846 WuXi AppTec (02359 HK) issued a profit forecast. It is estimated that last year's net profit increased by 50 to 60%, about 927 million to 1.112 billion yuan, mainly due to the rapid growth of overseas customer orders in the second half of the year, the continuous improvement of capacity utilization and operating efficiency. Revenue grew strongly, rising by more than 30% year-on-year in the second half of the year. WuXi AppTec reached a record high of RMB 203.8 and is now up 11%. Its subsidiary WuXi Biologics (02269 HK) also broke the top, rising 8% to RMB 124.

WUXI APPTEC (02359 HK) Sees FY20 NP Up 50%-60% http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1070989/hk-stock-news WUXI APPTEC  has issued a positive profit alert, expecting a 50% to 60% growth in the net profit attributable to shareholders for the year of 2020 as compared with RMB1.855 billion for the year of 2019.

Citi: First to WuXi AppTec (02359) with a target price of HK$236, rating "Buy" https://finance.sina.cn/hkstock/ggyw/2021-01-20/detail-ikftpnnx9695874.d.html?from=wap Citi released a research report that China's pharmaceutical R&D outsourcing and production outsourcing (CRO/CDMO) companies have relatively good cost efficiency and a growing talent pool, and are the first to give the next four companies a "buy" rating.   ... Citi stated that the cost of Chinese pharmaceutical outsourcing companies is 30%-60% lower than that of manufacturers in developed countries. CRO/CDMO companies in China are less affected by public health incidents. According to data from consulting firm Frost & Sullivan, the Chinese R&D outsourcing market The scale in 2019 is US$6.9 billion, and it is expected to reach US$16.9 billion in 2023. The above four companies are the leaders in their fields, and the compound annual growth rate of profit in 2019-2023 is expected to be between 24%-40%.

http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1070604/hk-stock-news Citi initiates WUXI APPTEC at Buy with TP $236